Apellis Pharmaceuticals, Inc. (APLS) Stock
APLS has an Alpha Score of 38 out of 100 (weak), computed on Nov 4, 2026 from 2 of 4 sub-scores. Its trailing P/E ratio is 39.4 and its net margin 12.1% (key statistics as of Nov 11, 2026).
What is APLS's Alpha Score?
How it works →Alpha Score of 38 reflects weak overall profile with poor value, strong quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 4, 2026
A rules-based research rating, not a recommendation to buy or sell.
What are APLS's key statistics?
Key statistics as of Nov 11, 2026
How does APLS's valuation compare with the Healthcare sector?
| Metric | APLS | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 39.4 | 29.8 | 115 |
| Net margin | 12.06% | 3.60% | 175 |
| Return on equity | 39.71% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
APLS price chart
Powered by TradingViewWhat does Apellis Pharmaceuticals, Inc. do?
Apellis Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds that inhibit the complement system to treat autoimmune and inflammatory diseases. Its key products include EMPAVELI, approved for paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE, indicated for geographic atrophy secondary to age-related macular degeneration. The company targets complement-mediated rare diseases in ophthalmology, hematology, and nephrology through its C3 complement science platform. Apellis Pharmaceuticals Inc. maintains collaborations, such as with Swedish Orphan Biovitrum AB for pegcetacoplan development and commercialization, and with Beam Therapeutics Inc. for base editing technologies in complement-driven diseases. Founded in 2009 and headquartered in Waltham, Massachusetts, it plays a significant role in advancing targeted therapies for conditions with high unmet medical needs in the biopharmaceutical sector.